Atrial fibrillation and microRNAs

Gaetano Santulli1,2,3*, Guido Iaccarino4,6, Nicola De Luca2, Bruno Trimarco1 and Gianluigi Condorelli6,7

1 Department of Advanced Biomedical Sciences, “Federico II” University Hospital, Naples, Italy
2 Department of Translational Medical Sciences, “Federico II” University Hospital, Naples, Italy
3 Columbia University Medical Center, College of Physicians & Surgeons, New York Presbyterian Hospital - Manhattan, New York, NY, USA
4 Department of Medicine and Surgery, University of Salerno, Salerno, Italy
5 IRCCS “Multimedica,” Milano, Italy
6 Humanitas Clinical and Research Center, Rozzano (Milan), Italy
7 University of Milan, Milan, Italy

Edited by:
Zhilin Qu, University of California, Los Angeles, USA

Reviewed by:
David R. Van Wagoner, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, USA
Gemma Vilahur, Cardiovascular Research Center CSIC-I CCC, Spain

*Correspondence:
Gaetano Santulli, Columbia University Medical Center, College of Physicians & Surgeons, New York Presbyterian Hospital - Manhattan, 1150 Saint Nicholas Avenue, New York, 10032 NY, USA
e-mail: gs2620@columbia.edu

Atrial fibrillation (AF) is the most common sustained arrhythmia, especially in the elderly, and has a significant genetic component. Recently, several independent investigators have demonstrated a functional role for small non-coding RNAs (microRNAs) in the pathophysiology of this cardiac arrhythmia. This report represents a systematic and updated appraisal of the main studies that established a mechanistic association between specific microRNAs and AF, focusing both on the regulation of electrical and structural remodeling of cardiac tissue.

Keywords: atrial fibrillation, microRNA (miRNA), electrical remodeling, apoptosis, structural remodeling, electrophysiology, fibrosis

MicroRNA

MicroRNAs (miRs) are an evolutionarily conserved class of small (~22 nucleotides) non-coding RNAs (Ambros, 2004; Gan et al., 2013), first discovered in Caenorhabditis elegans (Ruvkun and Giusto, 1989; Ruvkun et al., 1989). They represent a vital component of genetic regulation, existing in virtually all organisms, suggesting thereby a pivotal role in biological processes (Latronico and Condorelli, 2008; Thum et al., 2008). Indeed, miRs are important regulators of gene expression in numerous biological processes including cellular proliferation, differentiation, and tumorigenesis (Care et al., 2007; Dvinge et al., 2013; Shen et al., 2013; Song et al., 2013). Typically, miRs are regarded as negative regulators of gene expression that inhibit translation and/or promote mRNA degradation by base pairing to complementary sequences within the 3′-untranslated region (3′-UTR) of protein-coding mRNA transcripts (Van Rooij and Olson, 2012; Meijer et al., 2013). Generally, mRNA degradation accounts for the majority of miR activity (Guo et al., 2010). Hence, by altering levels of key regulators within complex genetic pathways, miRs provide a posttranscriptional level of control of homeostatic and developmental events (Callis et al., 2009; Yates et al., 2013).

It is estimated that miRs regulate over 60% of all protein-coding genes (Friedman et al., 2009; Akerman and Mukherjee, 2013; Leucci et al., 2013). Considering that a single miR can regulate multiple miRNAs and that each mRNA may be a target of multiple miRs, the possible pathways for miR-dependent regulation of protein abundance seem to be extremely complicated (Akerman and Mukherjee, 2013; Santulli and Totary-Jain, 2013). In this model, a biologic response would be expected only after co-expression of various miRs that cooperatively target different components of a functional network (Liu et al., 2012; Van Rooij and Olson, 2012) or are all required to sufficiently repress a single target (Lagos-Quintana et al., 2001; Kim, 2013).

BIOMATURATION AND BIOLOGICAL ACTION OF miRs

Maturation of miRs involves a multi-stepped process (Bartel, 2004; Cullen, 2004) that starts from the transcription (mainly operated by RNA polymerase II) of single-stranded non-protein-coding RNAs, which are either transcribed as stand alone transcripts (intragenic miRs), often encoding various miRs, or generated by the processing of introns of protein-coding genes (intragenic or intronic miRs).

Transcription of intragenic miRs leads to the formation of primary miRs (pri-miR) with a characteristic hairpin or stem-loop structure (Denli et al., 2004), which are subsequently processed by the nuclear RNase III, Drosha (Zeng et al., 2001), and its partner proteins, among which there is the DiGeorge Syndrome Critical Region 8 (DGCR8, known as Pasha in invertebrates), named for its association with DiGeorge Syndrome (Shiohama et al., 2003; Roth et al., 2013), to become precursor miRs (pre-miRs). On the other hand, intronic miRs are obtained by the regular transcription of their host genes and then spliced to form looped pre-miRs, bypassing thereby the Drosha pathway (Bartel, 2004; Ruby et al., 2007).

Pre-miRs are exported from the nucleus in the cytoplasm in a process involving the Ran-GTP-dependent shuttle Exportin-5 (Lund et al., 2004). Once in the cytosol, the pre-miR hairpin is cleaved by the RNase III enzyme Dicer (Saxena and Tabin, 2004).
Atrial fibrillation (AF) is a highly prevalent disease with a significant genetic component (Den Hoed et al., 2013; Mahida, 2013; Santulli, 2013), considered the most common sustained arrhythmia, which can cause or exacerbate heart failure and represents an important risk factor for ischemic stroke (Fye, 2006; Conen et al., 2011; Santulli, 2012b; Santulli et al., 2013; Thomas and Sorrentino, 2014). AF represents the most commonly seen arrhythmia worldwide, especially in the geriatric population (Huikuri, 2008; Riley and Manning, 2011; Santulli et al., 2012c; Santulli and Iaccarino, 2013) and is associated with a substantially pronounced morbidity and mortality (Beyerbach and Zipes, 2004; Santulli, 2012a; Garg and Akoum, 2013; Menezes et al., 2013). From a pathophysiologic point of view, AF is characterized by atrial electrical remodeling, mainly mediated by ion-channel alterations (Brundel et al., 2001; Santulli et al., 2012b; Xie et al., 2013) and structural remodeling (fibrosis and apoptosis), which favors arrhythmia recurrence and maintenance (Perino et al., 2011; Santulli and D’Ascia, 2012; Santulli et al., 2012b). A noticeable feature of the electrical remodeling associated with AF is the abbreviation of the effective refractory period favoring reentry (D’Ascia et al., 2010, 2011; Kapur and Macrae, 2013), primarily due to shortening of atrial action potential duration (APD).

Three potential models have been proposed to explain the pathophysiology of AF (Jalife, 2011), albeit the precise relationship of each of these conceptual frameworks to human AF remains under investigation (Vikman et al., 2005; Kapur and Macræ, 2013; Shah et al., 2013):

The focal mechanism theory suggests that AF is provoked by the rapid firing of single or multiple ectopic foci, and also proposes a functional role for continued ectopic firing in the maintenance of AF (Lee et al., 2013).

The single circuit re-entry theory of AF assumes the presence of a single dominant reentry circuit alongside with the fragmentation of emanating waves in the heterogeneous electrical substrate of normal atrial tissue (Zemlin and Pertsov, 2007; Kapur and Macræ, 2013).

The multiple wavelet theory of AF stands on the notion that multiple reentry circuits exist, with randomly propagating wavefronts that must find receptive tissue in order to persist (Haissaguerre et al., 2013).

Slowing of conduction velocities and shortening of the refractory period of atrial myocytes (both central features of the electrical remodeling seen in AF) might help to stabilize the arrhythmia by decreasing circuit size. Of course these mechanistic models are not mutually exclusive. They may coexist in a single subject at various stages in the pathogenesis of AF and each may be applicable to certain subgroups of AF patients (Lindgren et al., 2003; Brieger and Freedman, 2009; Ruwald et al., 2013). Theoretically, all the miRs that are directly or indirectly involved in one of these processes, which are eventually based on the regulation of structural or electrical remodeling (cardiac automaticity, ion channels, fibrosis, and apoptosis), could participate in AF induction or perpetuation.

**EXPERIMENTAL STRATEGY TO IDENTIFY miRs INVOLVED IN HUMAN DISEASE**

The most common experimental approach to identify the specific miRs that play a role in a certain disease mainly consists of three phases: (1) Use a microarray matrix to recognize a list of miRs that are differentially expressed in subjects with the disease compared to control subjects (Frezetti et al., 2011; Jayaswal et al., 2011); (2) assess the putative target site efficacy by using bioinformatics-based algorithms or other computational tools that score potential interactions between microRNAs and mRNAs (Witkos et al., 2011); (3) validate *in vitro* (*or in vivo*) the existence of an inverse correlation between the expression levels of the miR and protein levels of its target gene(s). Another biological validation could be also achieved using a reporter system or other assays to prove that the binding of the miR and the target mRNA occurs within a RISC complex (Ling et al., 2013).

**FUNCTIONAL ROLE OF miRs IN ATRIAL FIBRILLATION**

Growing evidence demonstrates that miRs regulate several properties of cardiac physiology and excitability, including automaticity, Ca²⁺ handling, conduction, and repolarization (Grueter et al.,
In particular, recent reports have unveiled an essential role of miRs in regulating cardiac excitability and arrhythmogenesis (Callis et al., 2009; Shan et al., 2009). These studies have primarily focused on the two muscle-specific miRs, i.e., miR-1 and miR-133, which are among the most abundantly expressed miRs in the heart (Liang et al., 2007; Wang et al., 2011).

However, lately other ubiquitously distributed miRs, such as miR-328 have been shown to exhibit a strong arrhythmogenic potential (Lu et al., 2010). It is likely that multiple miRs contribute to controlling arrhythmogenicity of the heart and that different miRs are involved in different types of arrhythmias under different pathological conditions of the heart (Horie et al., 2012; Kochegarov et al., 2013; Qiao et al., 2013; Zhang et al., 2013a). The most important miRs so far implicated in the pathophysiology of AF, regulating both electrical and structural remodeling, are reported in Table 1, alongside with their target gene(s) and function(s).

Although circulating miRs seem to be interesting candidates as biomarkers in AF patients, they still possess several important limitations (Quiat and Olson, 2013; Santulli and Totary-Jain, 2013). Indeed, at the moment there is no good natural stable housekeeping control for circulating miRs, which may result in strong variations, and they are generally present in low amounts in plasma and serum.

### REGULATION OF PROTEINS INVOLVED IN ELECTRICAL REMODELING BY miRs

As mentioned above, arrhythmogenesis is essentially attributed to enhanced triggered activity, and several studies have attributed such activity to alterations in different ion channels, including a peculiar instability in Ca\(^{2+}\) handling (Ter Keurs and Boyden, 2012; Boon et al., 2013; Heymans et al., 2013; Latronico and Condorelli, 2013). The most important miRs so far implicated in the pathophysiology of AF, regulating both electrical and structural remodeling, are reported in Table 1, alongside with their target gene(s) and function(s).

### Table 1 | miRs with an established role in the regulation of cardiac electrical and structural remodeling.

| miR     | Changes in AF | Main target genes and their function                      | References                      |
|---------|--------------|----------------------------------------------------------|---------------------------------|
| miR-1   | Down-regulated | KCNJ2, GJA1 (connexin43), Fibulin-2 | Increased I\(_{K1}\), Altered conduction, Increased fibrosis | Zhao et al., 2007; Girmatsion et al., 2009 |
| miR-21  | Up-regulated  | Spry1, PDCD4                                             | Inhibition of fibroblast proliferation | Adam et al., 2012 |
| miR-26  | Down-regulated | KCNJ2                                                   | Increased I\(_{K1}\)            | Luo et al., 2013 |
| miR-29  | Down-regulated | Fibrillin, collagen-1A1, collagen-3A1, Mcl-2             | Increased fibrosis              | Dawson et al., 2013 |
| miR-30  | Down-regulated | CTGF                                                    | Increased fibrosis              | Duisters et al., 2009 |
| miR-133 | Down-regulated | CTGF, TGF-β                                             | Increased fibrosis              | Cooley et al., 2012 |
| miR-328 | Up-regulated  | CACNB1, CACNA1C                                          | Shortened atrial action potential duration | Lu et al., 2010 |
| miR-499 | Up-regulated  | KCNN3                                                   | Altered conduction              | Ling et al., 2013 |

AF, Atrial fibrillation; KCNJ2, K\(^+\) inwardly-rectifying channel, subfamily J, member 2; GJA1, Gap junction alpha1 protein; SPRY1, sprouty homolog 1; Mcl-2, Myeloid cell-leukemia-2; CTGF, Connective tissue growth factor; TGF-β, Transforming growth factor β; KCNN3, K\(^+\) intermediate/small conductance Ca\(^{2+}\)-activated channel.
miR-223, miR-328, and miR-664 were found to be upregulated by >2 fold in AF samples (Lu et al., 2010), and further investigations are required to establish the molecular mechanism underlying such a change in the miR transcriptome.

Most recently, Ling and colleagues found a strong association between mir-499, which is significantly up-regulated in atrial tissue from AF patients, and KCNJ3, the gene that encodes the small-conductance Ca\(^{2+}\)-activated K\(^+\) channel 3 (SK3), possibly contributing to the electrical remodeling observed in AF (Ling et al., 2013).

**REGULATION OF PROTEINS INVOLVED IN STRUCTURAL REMODELING BY miRs**

Fibrosis is the hallmark of structural cardiac remodeling (Allessie et al., 2002; Nguyen et al., 2013). Structural changes in the atria of AF patients have been identified (Anyukhovsky et al., 2012) between matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs).

In addition to the regulation of key proteins involved in electrical remodeling, miR-1 also modulates cardiac fibrosis, through means of its target protein Fibulin-2, a secreted protein implicated in ECM remodeling (Karakikes et al., 2013). An intriguing role for miR-21 and its downstream target Sprouty (Spry1), a role for miR-21 and its downstream target Sprouty (Spry1), a direct or indirect post-transcriptional regulator of genes implied disposing pathological changes. The functional role of miRs as direct or indirect post-transcriptional regulators of genes implied in electrical and/or structural remodeling strongly suggest that these miRs may serve as potential biomarkers or promising drug targets, in prevention, treatment, and management of AF.

**REFERENCES**

Adam, O., Lohfelm, B., Thum, T., Gupta, S. K., Puhl, S. L., Schafer, H. J., et al. (2012). Role of miR-21 in the pathogenesis of atrial fibrosis. *Basic Res. Cardiol.* 107, 278. doi: 10.1007/s00395-012-0278-0

Akerman, A. W., and Mukherjee, R. (2013). MicroRNAs emerging as mediators of remodeling with atrial fibillation. *Heart Rhythm* 10, 1010–1011. doi: 10.1016/j.hrthm.2013.03.021

Ali, R., Huang, Y., Maher, S. E., Kim, R. W., Giordano, F. J., Tellides, G., et al. (2012). miR-1-mediated suppression of Sorcin regulates myocardial contractility through modulation of Ca2+ signaling. *J. Mol. Cell. Cardiol.* 52, 1027–1037. doi: 10.1016/j.yjmcc.2012.01.020

Allessie, M., Ausma, J., and Schotten, U. (2002). Electrical, contractile and structural remodeling during atrial fibillation. *Cardiovasc. Res.* 54, 230–246. doi: 10.1016/S0008-6633(02)00258-4

Ambros, V. (2004). The functions of animal microRNAs. *Nature* 431, 350–355. doi: 10.1038/nature02871

Ambros, V., Bartel, B., Bartel, D. P., Burge, C. B., Carrington, J. C., Chen, X., et al. (2003). A uniform system for microRNA annotation. *RNA* 9, 277–279. doi: 10.1210/rna.2183803

Anderson, M. E., and Mohler, P. J. (2007). MicroRNA may have macro effect on sudden death. *Nat. Med.* 13, 410–411. doi: 10.1038/nm0407-410

Ando, Y., Yang, G. X., Kenny, T. P., Kawata, K., Zhang, W., Huang, W., et al. (2013). Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-beta receptor type II mouse. *Autoimmun.* 41, 111–119. doi: 10.1016/j.jaut.2012.12.013

Anyukhovsky, E. P., Susonov, E. A., Chandra, P., Rosen, T. S., Boyden, P. A., Dangio, P., et al. (2005). Age-associated changes in electrophysiologic remodeling: a potential contributor to initiation of atrial fibrillation. *Cardiovasc. Res.* 66, 353–363. doi: 10.1016/j.cardiores.2004.10.033

Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 116, 281–297. doi: 10.1016/S0092-8674(04)00045-5

Beyerbach, D. M., and Zipes, D. P. (2004). Mortality as an endpoint in clinical trials of antiarrhythmic drugs. *J. Am. Coll. Cardiol.* 43, 926–932. doi: 10.1016/S0735-1097(00)01195-5

Boon, R. A., Jekushi, K., Lechner, S., Seeger, T., Fischer, A., Heydt, S., et al. (2013). MicroRNA-34a regulates cardiac ageing and apoptosis. *Nature* 495, 107–110. doi: 10.1038/nature11919

Brieger, D. B., and Freedman, S. B. (2009). Delirium cordis: can we predict the onset of atrial fibrillation? *Lancet* 373, 698–700. doi: 10.1016/S0140-6736(09)60415-3

Brundel, B. J., Van Gelder, I. C., Henning, R. H., Tuinenburg, A. E., Wietses, M., Grandjean, J. G., et al. (2001). Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and miRNA levels for K+ channels. *J. Am. Coll. Cardiol.* 37, 926–932. doi: 10.1016/S0735-1097(00)01195-5

Callis, T. E., Pandya, K., Seok, H. Y., Tang, R. H., Tatsuguchi, M., Huang, Z. P., et al. (2009). MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. *J. Clin. Invest.* 119, 2772–2786. doi: 10.1172/JCI36154

Care, A., Catalucci, D., Felicetti, E., Bonci, D., Addario, A., Gallo, P., et al. (2007). MicroRNA-133 controls cardiac hypertrophy. *Nat. Cell Biol.* 13, 613–618. doi: 10.1038/nmc0812-618

Conen, D., Chae, C. U., Glynn, R. J., Tedrow, B. U., Everett, B. M., Buring, J. E., et al. (2011). Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. *JAMA* 305, 2080–2087. doi: 10.1001/jama.2011.659

Cooley, N., Cowley, M. J., Lin, R. C., Marasco, S., Wong, C., Kaye, D. M., et al. (2012). Influence of atrial fibrillation on microRNA expression profiles in left and right atria from patients with valvular heart disease. *Physiol. Genomics* 44, 211–219. doi: 10.1152/physiolgenomics.00111.2011

Cullen, B. R. (2004). Transcription and processing of human microRNA precursors. *Mol. Cell* 16, 861–865. doi: 10.1016/j.molcel.2004.12.002
Song, S. J., Poliseno, L., Song, M. S., Ala, U., Webster, K., Ng, C., et al. (2013). MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 154, 311–324. doi: 10.1016/j.cell.2013.06.030

Straten, P., and Andersen, M. H. (2010). The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens. Oncotarget 1, 239–245.

Ter Keurs, H. E., and Boyden, P. A. (2007). Calcium and arrhythmogenesis. Physiol. Rev. 87, 457–506. doi: 10.1152/physrev.00011.2006

Thomas, I. C., and Sorrentino, M. J. (2014). Bleeding risk prediction models in atrial fibrillation. Curr. Cardiol. Rep. 16, 432. doi: 10.1007/s11886-013-0432-9

Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., et al. (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980–984. doi: 10.1038/nature07511

Van Rooij, E., and Olson, E. N. (2012). MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 11, 860–872. doi: 10.1038/nrd3864

Zemlin, C. W., and Pertsov, A. M. (2007). Bradycardic onset of spiral wave re-entry: structural substrates. Europace 9(Suppl. 6), vi59–vi63. doi: 10.1093/europace/eum205

Zhang, R., Niu, H., Ban, T., Xu, L., Li, Y., Wang, N., et al. (2013a). Elevated plasma microRNA-1 predicts heart failure after acute myocardial infarction. Int. J. Cardiol. 166, 259–260. doi: 10.1016/j.ijcard.2012.09.018

Zhang, Y., Sun, L., Zhang, Y., Liang, H., Li, X., Cai, R., et al. (2013b). Overexpression of microRNA-1 causes atrioventricular block in rodents. Int. J. Biol. Sci. 9, 455–462. doi: 10.7150/ijbs.4630

Zhang, Y., Huang, Z. J., Dai, D. Z., Feng, Y., Na, T., Tang, X. Y., et al. (2012). Downregulated FKBP12.6 expression and upregulated endothelin signaling contribute to elevated diastolic calcium and arrhythmogenesis in rat cardiomyopathy produced by l-thyroxin. Int. J. Cardiol. 130, 463–471. doi: 10.1016/j.ijcard.2008.05.018

Zhao, Y., Ransom, J. F., Li, A., Vedantham, V., Von Drehle, M., Muth, A. N., et al. (2007). Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129, 303–317. doi: 10.1016/j.cell.2007.03.030

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 03 December 2013; accepted: 08 January 2014; published online: 24 January 2014.

Citation: Santulli, G, Iaccarino, G, De Luca, N, Trimarco, B and Condorelli, G (2014) Atrial fibrillation and microRNAs. Front. Physiol. 5:15. doi: 10.3389/fphys.2014.00015

This article was submitted to Cardiac Electrophysiology, a section of the journal Frontiers in Physiology.

Copyright © 2014 Santulli, Iaccarino, De Luca, Trimarco and Condorelli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.